Patanjali Ayurved’s FY20 net up 21.56 pc to Rs 424.72 cr, Net sales up 5.8 pc to Rs 9,022.71 cr

By: |
November 13, 2020 5:38 PM

While the company's revenue from operations was at Rs 9,022.71 crore, up 5.86 per cent, for the financial year ended on March 31, 2020. It was at Rs 8,522.68 crore in the year-ago period. Its total revenue was at Rs 9,087.91 crore in FY 2019-20, as against Rs 8,541.57 crore in the financial year ended March 31, 2019.

In an interview to FE last year, managing director and co-founder Acharya Balkrishna had said the company was working to plug gaps in the supply chain and expected to post decent revenue in FY20.

Haridwar-based Patanjali Ayurved Ltd has reported a 21.56 per cent increase in standalone net profit at Rs 424.72 crore for financial year 2019-20, according to data provided by business intelligence platform Tofler. The company had reported a net profit of Rs 349.37 crore for the 2018-19 financial year, it said.

While the company’s revenue from operations was at Rs 9,022.71 crore, up 5.86 per cent, for the financial year ended on March 31, 2020. It was at Rs 8,522.68 crore in the year-ago period. Its total revenue was at Rs 9,087.91 crore in FY 2019-20, as against Rs 8,541.57 crore in the financial year ended March 31, 2019.

Total expenses of Patanjali Ayurved were up 5.34 per cent to Rs 8,521.44 crore. Profit Before Tax of the yoga guru Ramdev-promoted organisation was up 25.12 per cent to Rs 566.47 crore for FY 2019-20. It was Rs 452.72 crore in the year-ago period, as per the data.

Its revenue from ‘other income’ was up three fold during the fiscal under review to Rs 65.19 crore, from Rs 18.89 crore of the FY 2018-19. Commenting on the results, Swami Ramdev told PTI: “Last fiscal was very challenging for us, in which we had acquired Ruchi Soya. Despite financial challenges, we have worked uninterrupted.”

While talking about the outlook, Ramdev said this fiscal, the company would have “unparalleled growth” as consumers are having more trust on Patanjali’s product because of “purity and faith” along with its “affordability”.
“We would have higher growth this fiscal than the previous fiscal and higher turnover,” he said.

Some segments as Divya Pharmacy, its ayurvedic manufacturing unit, would have higher growth.
“Even during the lockdown, except some days when movement was not allowed, we have not stalled our services. Other companies took one to two months to handle the situation… we started the production from the first day as we have our own transportation and distribution lines,” he said.

Patanjali Ayurved is mainly into Fast-moving consumer goods (FMCG) business and ayurvedic medicines.
The company’s biscuit, noodles, dairy businesses, solar panel, apparel businesses and transportation are not part of Patanjali Ayurved.

In December last year, the Haridwar-based group had completed the acquisition of bankrupt Ruchi Soya for Rs 4,350 crore, maker of soya food brand Nutrela through an insolvency process.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1RNLI takes 40,000 sq ft on lease at BKC’s Adani Inspire to house corporate HQ
2IATA urges Centre to support Indian airlines to tide over COVID crisis
3Nasscom: Over 50% tech startups see revenue reaching pre-Covid level in 6 months, cash in hand improves